Global Neurological Biomarkers Market 2016-2020
Biomarkers are the indicators considered for identifying specific diseases. They are mainly used for identification of the progress of a particular disease and evaluation of an effective method for drug target identification. The biomarkers specifically involved in the identification of the neurological disorders are called neurological biomarkers.
Technavio’s analysts forecast the global neurological biomarkers market to grow at a CAGR of 15.48% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global neurological biomarkers market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of neurological biomarkers.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Neurological Biomarkers Market 2016-2020
Technavio recognizes the following companies as the key players in the global neurological biomarkers market: Myriad RBM, Proteome Sciences, QIAGEN, and Thermo Fisher Scientific.
Other Prominent Vendors in the market are: AbaStar MDx, Abiant, Acumen Pharmaceuticals, Aepodia, Alseres Pharmaceuticals, Athena Diagnostics, Banyan Biomarkers, Cisbio Bioassays, Diagenic, Proteosys, and Psynova Neurotech.
Commenting on the report, an analyst from Technavio’s team said: “Integrated biology approach will be the key focus area and a key trend for market growth. Single-cell biosensors have already been developed for protein and DNA biomarkers. The development of nanosensors, which can be used for neuro-based analytes, is expected to emerge. For example, BRAF tests for neuropathology is under research. Software like Genedata Expressionist that can integrate and analyze data from different omics platforms and deliver meaningful clinical biomarkers will be the next focus. Systems Biology approaches will enter into routine use for biomarker validation, pre-clinical drug development, and clinical trials (virtual patients) in the next 4-5 years. Multi-marker blood-based tests that can diagnose and differentiate between closely related neurodegenerative disorders will be a critical emerging area.”
According to the report, one of the key drivers for market growth will be increasing focus toward drug discovery applications. Close to 1% of medications in the biomarker discovery and development pipeline achieve the commercial success. The rate of failure cases is too high, and very frequently drug candidates fail in the late development phase. This has led to the evolution of alternative biomarker-based techniques by contract research organizations and manufacturers.
Further, the report states that unmet market needs will be a challenge for the market. The inability to give convincing proof regarding the clinical and financial advantages of introducing new biomarker-based diagnosis methods are recognized as the main challenge for moderate uptake of new biomarkers. Genuine limitations, such as reproduction of positive clinical trial result, the absence of early pre-analytical examinations, the absence of autonomous check of results, and failure of investigators to assess whether the use of the biomarker would improve clinical practice to the benefit of neuro patients are hindering diagnostic neurological biomarker validation. Innovative evaluation of fluid-based proteomics enables biomarkers identification as indicators of the onset of neurological disease have been complex and incurs high research cost.
Myriad RBM, Proteome Sciences, QIAGEN, Thermo Fisher Scientific, AbaStar MDx, Abiant, Acumen Pharmaceuticals, Aepodia, Alseres Pharmaceuticals, Athena Diagnostics, Banyan Biomarkers, Cisbio Bioassays, Diagenic, Proteosys, Psynova Neurotech.